Low B cell counts as risk factor for infectious complications in systemic sclerosis after autologous hematopoietic stem cell transplantation.
Autologous hematopoietic stem cell transplantation
B cells
CMV reactivation
Infectious complications
Systemic sclerosis
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
08 08 2020
08 08 2020
Historique:
received:
15
04
2020
accepted:
18
06
2020
entrez:
11
8
2020
pubmed:
11
8
2020
medline:
22
6
2021
Statut:
epublish
Résumé
Autologous hematopoietic stem cell transplantation (aHSCT) is a treatment option for a selected group of systemic sclerosis (SSc) patients with good available evidence but can be associated with considerable morbidity and mortality. The aim of this study was to describe infectious complications and distinct immune reconstitution patterns after aHSCT and to detect risk factors in lymphocyte subsets, which are associated with an elevated rate of infections after aHSCT. Seventeen patients with SSc were included in this single-center retrospective cohort study. Clinical and laboratory data was collected before and for 12 months after aHSCT, including immunophenotyping of peripheral whole blood by fluorescence-activated cell sorting. Cytomegalovirus (CMV) reactivations were common in CMV-IgG-positive patients (50%) and needed treatment. Mycotic infections occurred in 17.6%. One patient died (resulting in a mortality of 5.9%) due to pneumonia with consecutive sepsis. All patients showed decreased T helper cells (CD3 After aHSCT, monitoring for infectious complications, especially for CMV reactivations, is crucial as the reconstitution of the immune system takes longer than 12 months. Low peripheral B cells might be a risk factor for an elevated infection rate.
Sections du résumé
BACKGROUND
Autologous hematopoietic stem cell transplantation (aHSCT) is a treatment option for a selected group of systemic sclerosis (SSc) patients with good available evidence but can be associated with considerable morbidity and mortality. The aim of this study was to describe infectious complications and distinct immune reconstitution patterns after aHSCT and to detect risk factors in lymphocyte subsets, which are associated with an elevated rate of infections after aHSCT.
METHODS
Seventeen patients with SSc were included in this single-center retrospective cohort study. Clinical and laboratory data was collected before and for 12 months after aHSCT, including immunophenotyping of peripheral whole blood by fluorescence-activated cell sorting.
RESULTS
Cytomegalovirus (CMV) reactivations were common in CMV-IgG-positive patients (50%) and needed treatment. Mycotic infections occurred in 17.6%. One patient died (resulting in a mortality of 5.9%) due to pneumonia with consecutive sepsis. All patients showed decreased T helper cells (CD3
CONCLUSION
After aHSCT, monitoring for infectious complications, especially for CMV reactivations, is crucial as the reconstitution of the immune system takes longer than 12 months. Low peripheral B cells might be a risk factor for an elevated infection rate.
Identifiants
pubmed: 32771029
doi: 10.1186/s13075-020-02255-3
pii: 10.1186/s13075-020-02255-3
pmc: PMC7414656
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
183Références
Blood. 2009 Jan 1;113(1):214-23
pubmed: 18824594
N Engl J Med. 2018 Jan 4;378(1):35-47
pubmed: 29298160
Rheumatology (Oxford). 2018 Dec 1;57(12):2106-2113
pubmed: 30053212
Arthritis Rheum. 2005 May;52(5):1555-63
pubmed: 15880600
Lancet Respir Med. 2016 Sep;4(9):708-719
pubmed: 27469583
Arthritis Res Ther. 2019 Jan 22;21(1):30
pubmed: 30670057
Lancet. 2017 Oct 7;390(10103):1685-1699
pubmed: 28413064
Haematologica. 2020 Jan 16;:
pubmed: 31949011
Arthritis Res Ther. 2019 Apr 29;21(1):106
pubmed: 31036055
Arthritis Rheum. 2001 Jun;44(6):1351-8
pubmed: 11407694
Arthritis Rheum. 2013 Nov;65(11):2737-47
pubmed: 24122180
J Crit Care. 2018 Jun;45:71-75
pubmed: 29413726
Eur J Immunol. 2020 Jan;50(1):119-129
pubmed: 31424086
Ann Rheum Dis. 2017 Aug;76(8):1327-1339
pubmed: 27941129
Rheumatology (Oxford). 2012 Jun;51(6):1017-26
pubmed: 21900368
Blood. 1998 Sep 1;92(5):1471-90
pubmed: 9716573
Transpl Infect Dis. 2017 Apr;19(2):
pubmed: 28035717
N Engl J Med. 2006 Jun 22;354(25):2655-66
pubmed: 16790698
Haematologica. 2000 Aug;85(8):832-8
pubmed: 10942930
Semin Arthritis Rheum. 2017 Apr;46(5):625-631
pubmed: 27839742
Transpl Infect Dis. 2009 Aug;11(4):318-23
pubmed: 19453993
Arthritis Rheum. 2001 Apr;44(4):754-60
pubmed: 11315914
JAMA. 2014 Jun 25;311(24):2490-8
pubmed: 25058083
Lancet. 2011 Aug 6;378(9790):498-506
pubmed: 21777972
Eur J Haematol. 2006 Feb;76(2):102-8
pubmed: 16405430
Clin Exp Immunol. 2017 Sep;189(3):268-278
pubmed: 28498568
Bone Marrow Transplant. 2016 Apr;51(4):573-80
pubmed: 26726945
Clin Rheumatol. 2017 Jul;36(7):1649-1654
pubmed: 28293753